DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationGP

Neonatal abstinence and maternal-medicine exposure

Essential points for quick revision.

!
Respiratory depression, seizure or severe feeding failure

Apnoea, cyanosis, reduced consciousness, seizures, profound hypotonia, dehydration or uncontrolled vomiting requires emergency stabilisation and cannot be assumed to be uncomplicated withdrawal.

Action: Stabilise airway, breathing, circulation, temperature and glucose; call neonatal help and assess sepsis, HIE, metabolic disease and intracranial pathology. Obtain an exact maternal medicine and substance timeline, including prescribed opioids, benzodiazepines, antidepressants and medicines given during labour. Provide respiratory support as required. Avoid routine naloxone in an opioid-exposed newborn because it can precipitate abrupt withdrawal; seek toxicology and neonatal pharmacy advice.

Synopsis

Assess newborn effects of prescribed medicines and substance exposure without stigma, distinguish toxicity from withdrawal and other illness, prioritise parent-infant supportive care, and use local neonatal pharmacotherapy safely when functional impairment persists.

  • Use neonatal opioid withdrawal syndrome for opioid-specific withdrawal and neonatal abstinence syndrome when multiple drug classes may contribute; signs are clinical and nonspecific.
  • Obtain a non-judgemental history of prescriptions, over-the-counter products, substitution therapy, alcohol, nicotine, recreational substances, timing, dose, route and last exposure.
  • Opioid withdrawal commonly causes high-pitched cry, tremor, irritability, increased tone, poor sleep, yawning, sneezing, sweating, loose stool, vomiting and disorganised feeding.

Key red flags

Apnoea, bradycardia, cyanosis or marked sedation soon after birth suggests drug effect, respiratory disease, infection or HIE rather than withdrawal alone.

Investigation priorities

01
First-line: clinical and functional assessmentFirst stepFirst line

Establish whether the baby can feed, sleep, be consoled and maintain physiological stability.

Management branches

Before birthPlan exposure-aware care

A medicine or substance with possible newborn effects is identified antenatally.

  1. Obtain specialist risk assessment without abrupt maternal cessation.
  2. Agree birth-site, observation, feeding, breastfeeding, maternal analgesia and safeguarding plans.
After birthSupport regulation

The baby is stable but at risk of adaptation or withdrawal.

Key medicines

Morphine sulfate oral solutionOne current NHS Greater Glasgow and Clyde neonatal protocol starts 60 micrograms/kg orally every 4 hours for significant opioid withdrawal, increasing by 10 micrograms/kg per dose daily to a maximum 80 micrograms/kg every 4 hours before specialist review and later gradual weaning. Other UK units use different schedules.
Phenobarbital oral or intravenousUse only the exact neonatal loading, maintenance and level-monitoring regimen in the treating unit's formulary when specialist review identifies refractory symptoms or important non-opioid or polysubstance withdrawal.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom